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R E V I E W
Role of the vasodilator peptide angiotensin-(1–7) 
in cardiovascular drug therapy
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Abstract: The renin-angiotensin-system (RAS) is a cascade of enzymatic reactions resulting 
ultimately in the formation of angiotensin II. Recent research has expanded the knowledge 
about the RAS by adding new components to the pathways: angiotensin-(1–5) [Ang-1–5], 
angiotensin-(1–7) [Ang-(1–7)], angiotensin-(1–9) [Ang-(1–9)], an ACE homologous enzyme, 
ACE2, and the G-protein-coupled receptor mas as a molecular receptor for Ang-(1–7). Although 
previous studies provided some conﬂicting evidence about the relevance of Ang-(1–7) in the 
regulation of vascular and renal function, data now demonstrate that Ang-(1–7) contributes to 
the cardiovascular effects of ACE-inhibitors (ACE-I) and AT1-receptor-blockers (ARBs) both 
in experimental conditions and in humans. This review summarizes and critically discusses 
the currently available experimental and clinical study evidence for the role of Ang-(1–7) as a 
vasodilator and anti-trophic peptide in cardiovascular drug therapy. In addition, the potential 
therapeutic impact of currently available RAS blocking agents (ACE-I and ARBs) and new 
agents still under development (renin-inhibitors) on the RAS-effector peptides is highlighted.
Keywords: renin-angiotensin-system, cardiovascular drug therapy, Angiotensin-(1–7)
Introduction
The importance of the renin-angiotensin-system (RAS) in the development of hyper-
tension and cardiovascular disease is well established (Unger 2002). Chronic RAS 
activation has been identiﬁed as a major factor contributing to progressive dysfunction 
of end organs including blood vessels, the kidneys and the heart (Unger 2002). This 
prompted the development of agents, capable of blocking the RAS and reversing the 
associated pathologies.
The ﬁrst group of drugs targeting the RAS which became available in the late 
1970-ies were ACE-inhibitors (ACE-I) (Brunner et al 1978). Captopril was the ﬁrst 
ACE-I which was and still is clinically used for the treatment of hypertension. The ﬁrst 
– although peptide – AT1-receptor-blocker (ARB) saralasin was identiﬁed in 1971 (Pals 
et al 1971) and the antihypertensive effect demonstrated in patients in 1979 (Case 
et al 1979). Due to the lack of oral bioavailability this agent did not achieve wider clini-
cal use. More than ten years elapsed before the ﬁrst selective synthetic AT1-receptor 
antagonist (Losartan) became available for the treatment of hypertension (Johnston 
1995). It soon became clear that the reduction in cardiovascular events demonstrated 
in clinical trials with ACE-I (Yusuf et al 2000) and ARBs (Pitt et al 1997) was not only 
related to their blood pressure lowering capacity (Burnier and Brunner 2000; Hayoz 
2002; Cipollone et al 2004) but to a more complex effect in which reversal of target 
organ damage might be explained by inhibition of synthesis or activity of angiotensin 
II (Ang II) or transformation to a metabolite with pleiotropic activity.
The understanding of the RAS has been extended in the last few years with respect 
to the recognition that angiotensin-(1–7) [Ang-(1–7)] – a metabolite cleaved from 
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Ang I and Ang II – is a biologically active product of the 
renin-angiotensin cascade (Carey and Siragy 2003). This hep-
tapeptide has been recognized to counterbalance the effects of 
Ang II by stimulating the activity of vasodilator autocoids and 
nitric oxide (NO) (Ferrario et al 1997). The characterization 
of Ang-(1–7) (Schiavone et al 1988; Campagnole-Santos et 
al 1989; Ferrario et al 1991) as an amino-terminal angiotensin 
peptide product generated from either angiotensin I (Ang I) 
or Ang II provided a foundation for the pursuit of a new 
concept regarding the regulation of cardiovascular function 
by the RAS. While prostacyclin, bradykinin and NO act as 
vasodilator hormones limiting the pressor and proliferative 
actions of Ang II, it had not been considered that products 
derived independently from either angiotensin I (Ang I) or 
Ang II could also function to counterbalance the actions of 
Ang II.
This review focuses on the currently available evidence 
for the contribution of the vasodilator peptide Ang-(1–7) to 
the beneﬁcial effects of cardiovascular drugs blocking the 
RAS and discusses the different pharmacological actions of 
ACE-I and ARBs on the balance of different RAS-effectors 
and the potential of new concepts like vasopeptidase and 
renin inhibition.
Ang-(1–7)
Ang-(1–7) as an antagonist of angiotensin II
Eighteen years ago the presence of the heptapeptide Ang-
(1–7) as a product of the metabolism of Ang I found in brain 
homogenates (Santos et al 1988) led to the later demonstration 
of its action in counteracting the pressor and baroreﬂex effects 
of Ang II (Campagnole-Santos et al 1989; Benter et al 1993; 
Benter et al 1995a). The existence of biologically active frag-
ments, other than Ang II, suggests a process of biotransforma-
tion involving a cascade of multiple upstream enzymes but 
also raises the problem that the organization of the physiologi-
cal network determining the actions of Ang II needs revision 
to account for the actions of the additional peptides. Figure 1 
gives an overview about the pathways for the formation of 
biologically active angiotensin peptides. Two important and 
recently published ﬁndings provide strong evidence for an 
extended understanding of the RAS as a regulatory system 
which does not necessarily have to be pharmacologically 
inhibited in order to treat hypertension and RAS-mediated 
end-organ damage but which can be pharmacologically modi-
ﬁed by amplifying pathways generating Ang-(1–7). This has 
the potential to counterbalance the detrimental effects of Ang 
II: First, identiﬁcation of the ACE-homologue ACE2 which 
forms Ang-(1–7) from Ang II (Donoghue et al 2000; Tipnis 
et al 2000; Crackower et al 2002) and second the identiﬁca-
tion of the mas-receptor (Santos et al 2003) as molecular 
target structure for the Ang-(1–7)-molecule mediating its 
beneﬁcial effects.
Origin of Ang-(1–7)
Ang-(1–7) is a fragment of Ang I which can be cleaved 
by endopeptidases through the removal of the last three 
amino acids of the Ang I precursor molecule. The relative 
importance of the endopeptidases, prolyl endopeptidase 
24.26 (PEP), neutral endopeptidases (NEP) 24.11 (nepri-
lysin), and thimet oligopeptidase 24.15 in the conversion 
of Ang I into Ang-(1–7) appears to depend on both tis-
sue enzyme distribution and substrate availability since 
neprilysin is highly active in the circulation and vascular 
endothelium whereas in vascular smooth muscle Ang-
(1–7) formation is dependent on the hydrolytic activity of 
thimet oligopeptidase 24.15 (Welches et al 1993; Chappell 
et al 1994).
More recently, however, a pathway for Ang-(1–7) 
production has been demonstrated through the cloning and 
characterization of an ACE homologue – termed ACE2. This 
enzyme, shown to convert Ang II into Ang-(1–7) established 
a new pathway by which the trophic, vasoconstrictor, and 
pro-ﬁbrotic effects of Ang II would be mitigated by this 
alternate processing pathway (see Figure 1).
ACE2 was identiﬁed as a new homologue of ACE 
(Donoghue et al 2000; Tipnis et al 2000; Crackower et al 
2002) which – in contrast to ACE – is not inhibited by 
ACE-I nor does it share the same catalytic properties. The 
catalytic activity of ACE2 on Ang II as a substrate is much 
higher than its ability to cleave Ang-(1–9) from Ang I. 
ACE2 exhibits the highest efﬁcacy (kcat/km) among Ang-
(1–7)-forming enzymes and a 500-fold greater kcat/Km for 
Ang II compared with Ang I. Determination of the kcat/Km 
ratio gives a measurement of the substrate speciﬁcity. Thus, 
ACE2 appears to function to decrease Ang II concentration. 
ACE2 exists in both soluble and membrane-bound forms 
with high expression in the kidney, heart, cardiovascular 
tissues, brain and testes (Harmer et al 2002). Animal studies 
in the ACE2 knockout model demonstrated higher circulat-
ing and tissue levels of Ang II suggesting that reductions 
in ACE2 expression may lead to higher endogenous levels 
of Ang II and contribute to cardiac and renal patholo-
gies associated with this model (Crackower et al 2002). 
Therefore, ACE2 might have an important function as a 
counter-regulatory enzyme to decrease local cardiac Ang II 
concentrations.Vascular Health and Risk Management 2007:3(1) 127
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A way to degrade Ang-(1–7) is ACE which hydrolyses 
Ang-(1–7) to Ang-(1–5), thus regulating / limiting the physi-
ological effects of Ang-(1–7) (Chappell et al 1998; Deddish 
et al 1998).
Ang-(1–7) receptor
Several studies gave evidence for the existence of a non-
AT1/AT2-receptor that mediates the effects of Ang-(1–7) 
(Tallant et al 1991; Campagnole-Santos et al 1992; Diz and 
Pirro, 1992; Jaiswal et al 1992). This was obtained using 
the selective Ang-(1–7)-antagonist A-779 (Ambuhl et al 
1994; Santos et al 1994). In addition, studies in mas-recep-
tor transfected cells using Ang-(1–7) or the non-peptide 
Ang-(1–7)-agonist AVE-0991 showed that the mas-receptor 
mediates the effect of Ang-(1–7) on prostaglandins and NO 
release (Santos et al 2003; Pinheiro et al 2004). Recent studies 
using antisense probes directed to the cardiac mas receptor 
further showed abolition of the anti-hypertrophic effects of 
Ang-(1–7) on cardiac myocytes (Tallant et al 2005). These 
effects were not blocked by speciﬁc AT1– or AT2-receptor-
blockers. The mas proto-oncogene encodes a seven-trans-
membrane – domain G-protein-coupled orphan receptor that 
was erroneously identiﬁed as an Ang II receptor in the late 
1980ies. mas mRNA has been detected in the heart, testes, 
kidney, and the brain (Metzger et al 1995). Isolated hearts 
of mas-deﬁcient mice (see (Walther et al 1998) for details 
about the phenotype of mas-deﬁcient mice) showed marked 
changes in cardiac function. The interaction of Ang-(1–7) 
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Figure 1 Pathways for the formation of biologically active angiotensin peptides.
Abbreviations: ACE, angiotensin-converting enzyme; ACE2, ACE-related carboxypeptidase; CBP, carboxypeptidase; BK, bradykinine; CBP, carboxypeptidase; EDRF, endothe-
lium derived relaxing factor; NEP, neutral endopeptidase; NO, nitric oxide; PEP, prolylendopetidase; PKG, proteine kinase G.Vascular Health and Risk Management 2007:3(1) 128
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with its mas-receptor may have an important role in the 
regulation of cardiac function (Castro et al 2005). Today it 
is known that the mas-receptor mediates antiproliferative and 
antiarrhythmic effects, leads to vasodilation via bradykinin 
(BK) and NO-release, and stimulates renal sodium excretion 
and the sympathetic nervous system function.
Ang-(1–7) actions in preclinical 
studies
Renal actions of Ang-(1–7)
The RAS is a key regulator of kidney function, playing 
an essential role in the homeostasis of blood volume and 
hydro-electrolyte balance (Hall, 1991). Evidence suggests 
that not only Ang II but also Ang-(1–7) plays a signiﬁcant 
role in renal function. Ang-(1–7) has been described as a 
potent diuretic and natriuretic agent (Andreatta-van Leyen 
et al 1993; DelliPizzi et al 1994; Handa et al 1996). It in-
creases the renal blood ﬂow in anesthetized rats (Sampaio   
et al 2003) and produces afferent arteriolar relaxation through 
speciﬁc receptor-mediated NO-release in isolated kidneys 
of rabbits (Ren et al 2002). In humans, the concentration 
of Ang-(1–7) in renal veins is several times higher than in 
the systemic circulation (Admiraal et al 1990). In addition, 
Ang-(1–7) is excreted into the urine of normal healthy 
volunteers in amounts 2.5 fold higher than measured in the 
plasma (Ferrario et al 1998). Control studies in untreated 
hypertensive patients showed a signiﬁcantly reduced excre-
tion of Ang-(1–7). Importantly, urinary concentrations of 
Ang-(1–7) showed an inverse correlation with blood pressure 
and were suggestive for the association with hypertension. 
The relatively higher concentrations of Ang-(1–7) in urine 
compared with plasma provide evidence that locally pro-
duced Ang-(1–7) may contribute to the regulation of renal 
function.
Cardiovascular actions of Ang-(1–7)
Ang-(1–7) is formed (Santos et al 1992) and metabolized 
(Chappell et al 1998) in endothelial cells. Vasorelaxant 
effects of the peptide have been demonstrated in animals 
in several vascular beds (see Table 1). Ang-(1–7)-induced 
vasorelaxation mainly results from ampliﬁcation of bra-
dykinin-induced dilation, by stimulation of vasodilator 
prostaglandins and by mediation of NO-release. In some 
vascular beds data suggest a role for Ang-(1–7) in mediating 
EDRF – vasodilation. The biological actions of Ang-(1–7) 
are both activation of peripheral vasodilatory mechanisms 
and antitrophic effects mediated by the inhibition of protein 
synthesis (see Table 2). Ang-(1–7) exerts biological effects 
on three critical organ systems regulating blood pressure 
(brain, blood vessels, and kidney). The most important 
studies providing evidence for active vascular effects of 
Ang-(1–7) are summarized in Table 3. Preclinical studies 
Figure 2 Systematic overview of angiotensinogen (its crucial n-terminal part), angiotensin I, angiotensin II, and angiotensin-(1–7) with sites of enzymatic cleavage.
Angiotensinogen NH2-Asp-Arg-Val-Tyr-Ile -His-Pro-Phe-His-Leu-Val-Ile-His-Ser-R 
Angiotensin I  NH2-Asp-Arg-Val-Tyr-Ile-His -Pro-Phe-His-Leu-COOH
Angiotensin II  NH2-Asp-Arg-Val-Tyr-I le-His-Pro-Phe-COOH
Angiotensin-(1-7) NH2-Asp-Arg-Val-Tyr -Ile-His-Pro-COOH
Renin
E
ACEVascular Health and Risk Management 2007:3(1) 129
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demonstrate an important action of Ang-(1–7) in potentia-
tion of the vasodilator actions of bradykinin. Roks et al 
(1999) showed in human internal mammary arteries that 
contractions induced by Ang I and Ang II were antagonized 
by Ang-(1–7) in a non-competitive way, with a 60% inhibi-
tion of the maximal response to Ang II. The data further 
revealed an ACE-inhibiting effect by Ang-(1–7) in plasma 
and atrial tissue up to 100%. At supraphysiologic concen-
trations a vasoconstrictive effect of Ang-(1–7) has also 
been postulated – most likely through a weak AT1-receptor 
agonist action (Santos et al 2000). The observation that 
Ang-(1–7) increases following long-term-administration of 
ACE-I and ARBs (Santos et al 2000) raises the possibility 
that Ang-(1–7) might contribute to the pharmacological 
effects of both ACE-I and ARBs.
Interaction with bradykinin
Most of the interactions between Ang-(1–7) and bradykinin 
(BK) have been reported to occur in blood vessels 
(Paula et al 1995; Brosnihan et al 1996; Hecker et al 1997; Li 
et al 1997; Santos et al 2000; Almeida et al 2000; Fernandes 
et al 2001). Two major types of interactions are postulated: 
1. potentiation of BK by Ang-(1–7) and 2. mediation of the 
vascular actions of Ang-(1–7) by kinins. An overview about 
Table 1 Cardiovascular actions of Ang-(1–7)
Ang-(1–7) – effect  Model  Study
Ampliﬁcation of vasodilation mediated by bradykinin  Conscious rats  (Paula et al 1995)
Reduction of NE-release acting through a BK/NO-mediated  Hypertensive rat  (Gironacci et al 2004) 
mechanism stimulating cGMP/PKG-signaling
Coronary vasodilation mediated by NO  Canine coronary arteries in vitro  (Brosnihan et al 1996)
Release of vasodilator prostaglandins  Sprague-Dawley rats  (Benter et al 1993)
Reduction in plasma vasopressin concentration, blood pressure reduction  Hypertensive rats  (Benter et al 1995b)
Active vasodilation  Isolated rabbit afferent arterioles  (Ren et al 2002)
Bradykinin potentiation  Arterioles hypertensive rats in vivo  (Fernandes et al 2001)
Release of NO by Ang-(1–7)  Porcine coronary endothelium  (Porsti et al 1994)
Stimulation and release of vasodilator prostaglandins  Porcine aortic endothelial cells  (Jaiswal et al 1992)
Induction of bradykinin-mediated hypotensive responses  Anesthetized rat  (Abbas et al 1997)
Augmentation of bradykinin-induced vasodilation  Canine coronary artery rings  (Li et al 1997)
Endothelium-dependent relaxation  Canine middle cerebral artery  (Feterik et al 2000)
Cerebral vasodilation mediated by prostaglandins  Piglet pial arterioles  (Meng and Busija 1993)
Vasodilation mediated by EDRF  Feline mesenteric vascular bed  (Osei et al 1993)
Relaxation potentiated by losartan  Rat aorta  (le Tran and Forster 1997)
Vasodilation in the cutaneous and implant vasculature  Newly formed vasculatures   (Machado et al 2002)
  (sponge implants)
Bradykinin-induced vasodilation by Ang-(1–7)  Anestethized Wistar Rats  (Oliveira et al 1999)
Unmasking of a bradykinin mediated potentiation of ACE-inhibitors  Spontaneously hypertensive rats  (Fernandes et al 2001)
Abbreviations: See Figure 1.
Table 2 Biological actions of Ang-(1–7)
Organ or system  Biological action  Reference
Cellular actions  •  Stimulation of release of PGE2 and 6-keto-PGF1α  (Trachte et al 1990; Jaiswal et al 1992, 1993a, b; Benter et al 1995b)
  •  Augmentation of the vasodilator action of bradykinin  (Porsti et al 1994; Santos et al 1994; Paula et al 1995; Abbas  
      et al 1997; Li et al 1997; Lima et al 1997)
  •  Increased release of NO  (Osei et al 1993; Brosnihan et al 1996; Abbas et al 1997; Li et al  
      1997)
  •  Antiproliferative actions in vascular smooth muscle  (Freeman et al 1996)
Brain  •  Stimulation of vasopressin release  (Schiavone et al 1988; Baracho et al 1995; Santos et al 1996)
  •  Facilitation of baroreﬂexes  (Campagnole-Santos et al 1989; Campagnole-Santos et al 1992;  
      Silva et al 1993)
Blood vessels  •  Vasodilation and antihypertensive actions  (Benter et al 1993, 1995a, b)
Kidney  •  Diuresis and natriuresis  (DelliPizzi et al 1994; Handa et al 1996; Andreatta-van Leyen et al  
      1993; Hilchey and Bell-Quilley 1995)
  •  Inhibition of tubular sodium and bicarbonate transport  (Handa et al 1994, 1996)
Abbreviations: See Figure 1.Vascular Health and Risk Management 2007:3(1) 130
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the currently available study evidence demonstrating inter-
actions between bradykinin and Ang-(1–7) is summarized 
in Table 3. The mechanism underlying the BK potentiating 
activity of Ang-(1–7) is complex: There is considerable   
evidence for mas-receptor-mediated facilitation of NO release 
(Li et al 1997; Almeida et al 2000; Heitsch et al 2001) and/or 
prostaglandins (Paula et al 1995; Almeida et al 2000; Fer-
nandes et al 2001), endothelium-derived hyperpolarizing 
factor (Fernandes et al 2001), binding to ACE and because 
of that facilitation of the crosstalk between ACE and BK-B2 
receptors (Deddish et al 1998) and ACE-inhibition (Li et al 
1997; Chappell et al 1998). It is assumed that the relative 
contribution of each of these mechanisms changes from 
vascular bed to vascular bed, with species and probably with 
vessel diameter (Santos et al 2000).
Role of Ang-(1–7) as physiologic 
antagonist of angiotensin II
The ﬁrst study describing an interaction between Ang-(1–7) 
and Ang II was published by Bovy et al (1989) who described 
inhibition of the contractile effect of Ang II in the rabbit aorta 
by the Ang-(1–7) analogue Sar1-Ang-(1–7). Several studies 
conﬁrmed the ability of Ang-(1–7) to antagonize the vascular 
effects of Ang II (Mahon et al 1994; Roks et al 1999; Ueda 
et al 2000). Most evidence about the physiological actions 
of Ang-(1–7) has been demonstrated in animal models. 
However, there is also evidence from human studies: In a 
study performed in the arterial vascular bed of healthy young 
men, Ang-(1–7) was able to antagonize Ang II-induced 
vasoconstriction (Ueda et al 2000) by shifting the dose-
response-curve of Ang II to the right. Several mechanisms 
have been suggested for this interaction of Ang-(1–7) and 
Ang II in blood vessels:
•  The weak constrictive effect described in the study by 
Ueda (2000) (humans) and in the studies of Abbas (1997) 
and Benter (1995b) (animals) is mediated by low binding 
of Ang-(1–7) to the AT1-receptor causing an agonistic 
effect.
•  Interaction of Ang-(1–7) with extracellular Ca2+ inﬂux 
into smooth muscle cells might also contribute to this 
weak constrictive effect (Chansel et al 2001).
•  Because Ang-(1–7) does not antagonize the vasocon-
strictor action of α-adrenergic drugs in vitro (Mahon   
et al 1994) or in human forearm (Ueda et al 2000) it seems 
unlikely that these effects contribute to its antagonistic 
effects of Ang II-actions.
•  An inﬂuence of Ang-(1–7) on the synthesis of Ang II 
at the mRNA-level has been described (Moritz et al 
2001).
•  ACE-inhibiting properties of Ang-(1–7) have been 
described (Li et al 1997, Tom et al 2001) based on a 
crosstalk between ACE and the BK-B2 receptor and 
mas-receptor-mediated changes in the coupling and/or 
signalling of bradykinin.
•  A crosstalk between the mas-receptor and other recep-
tors such as AT1- and AT2-receptors may counterbalance 
constrictive pathways towards pathways resulting in 
vasodilation.
•  Ang-(1–7) potentiates the vasodilatory and hypotensive 
effects of bradykinin (Paula et al 1995; Oliveira et al 
1999; Almeida et al 2000; Tom et al 2001).
Interpretation of currently available study 
evidence with Ang-(1–7) in humans
All human trials investigating the cardiovascular effects 
of Ang-(1–7) are summarized in Table 4. Sasaki and   
Table 3 Interactions between Ang-(1–7), kinins, and Ang II in kidney and blood vessels
Action  Model  Reference
Potentiation of bradykinin  •  Normo- and hypertensive rats  •  (Santos et al 2000) 
by Ang-(1–7) by kinins      •  (Paula et al 1995)
      •  (Fernandes et al 2001)
  •  Canine coronary arteries  •  (Brosnihan et al 1996; Li et al 1997)
  •  Isolated rat hearts  •  (Almeida et al 2000)
  •  Conscious male Wistar rats  •  (Bomtempo et al 1998)
  •  Chinese hamster ovary cells transfected with human  •  (Deddish et al 1998) 
    cDNA for BK-B2 receptors and ACE
Mediation of Ang-(1–7)  •  Canine coronary arteries  •  (Brosnihan et al 1996; Li et al 1997) 
actions by kinins  •  Conscious male Wistar rats  •  (Bomtempo et al 1998)
  •  Bovine aortic endothelial cells  •  (Heitsch et al 2001)
  •  Anesthetized rats  •  (Abbas et al 1997)Vascular Health and Risk Management 2007:3(1) 131
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co-workers (Sasaki et al 2001) reported vasodilation in the 
human forearm whereas Davie and McMurray (Davie and 
McMurray 1999) did not observe an acute hemodynamic 
short-term effect of Ang-(1–7) in ACE-I treated patients. 
Failure to obtain a vasodilator response in patients given an 
ACE-I is not surprising as this treatment is associated with 
increased Ang-(1–7) levels due to both prevention of peptide 
metabolism by ACE and increased production from elevated 
levels of Ang I. In keeping with this interpretation, increased 
circulating Ang-(1–7)-levels have been clearly demonstrated 
in humans after therapy with RAS-inhibitors (Chappell et al 
1998; Iyer et al 1998b; Davie and McMurray 1999). Even 
if we assume that there is only a weak or even no agonistic 
short-term effect of Ang-(1–7) – infusion favoring vasodila-
tion in the human forearm vascular bed, this does not exclude 
hemodynamic effects in other vascular beds (eg, veins) or 
beneﬁcial long-term-effects after drug therapy with ACE-I 
or ARBs mediated by increases in Ang-(1-7)-peptide levels. 
It has to be noted that the long-term effects of ACE-I and 
ARBs on Ang-(1–7)-metabolism have not been investigated 
in humans so far.
Although it is not completely clear from human studies if 
exogenously infused Ang-(1–7) acts as a vasodilator (Wils-
dorf et al 2001), the available experimental evidence suggests 
that Ang-(1–7) contributes to the cardiovascular effects of 
ACE-I and ARBs by directly acting as an ACE-I or by an 
interaction with ACE favoring a crosstalk between the ACE-, 
the BK-B2- and the mas-receptor by mediating changes in 
coupling and signalling of bradykinin. However, randomized 
controlled studies systematically investigating the effects of 
RAS-blockade with ACE-I and ARBs on Ang-(1–7)-biology 
and catabolism have not been conducted. The main problem 
with the results obtained in human studies might be related 
to the extremely low case numbers included in clinical stud-
ies (usually n = 8) and to methodological differences in the 
study protocols. Therefore, the initiation of large random-
ized controlled clinical studies systematically investigating 
long-term-effects of pharmacological RAS-blockade on 
Ang-(1–7)-metabolism seems to be highly desirable.
We have recently demonstrated in healthy male subjects 
that a 4 week treatment period with 150 mg of the AT1-re-
ceptor-antagonist irbesartan results in signiﬁcant increases 
of Ang-(1–7) peptide levels which points towards a contri-
bution of Ang-(1–7) to the antihypertensive and beneﬁcial 
vascular effects of AT1-receptor blockade (Schindler et al 
2007). This study provides evidence that Ang-(1–7)-biol-
ogy might also be involved in humans when inhibitors of 
the RAS are being used.
In addition it has to be noted that the majority of 
published human studies points towards a RAS-modula-
tory role of Ang-(1–7) in humans (Roks et al 1999; Ueda 
et al 2000; Sasaki et al 2001; Ueda et al 2001) supporting 
vasodilation. Especially the recent data showing a role for 
ACE2 in cardiopulmonary pathophysiology (Reudelhu-
ber 2006) and clinical data from healthy human subjects 
(Schindler et al 2007) suggest that the effects of drug 
treatment with ACE-I and ARBs merit another look with 
regard to Ang-(1–7)-biology and its relevant signalling 
pathways.
Pharmacologic RAS inhibitors  
and Ang-(1–7)
Different actions of ACE-I and ARBs  
on the RAS
The general ability of ACE-I and of ARBs to attenuate virtu-
ally all of the cardiovascular actions of the RAS is commonly 
accepted (for review see (Dendorfer et al 2005)). Although 
ACE-I and ARB block the same system, they have important 
mechanistic differences because they act on different sites 
of the RAS (Burnier and Brunner 2000). The differences 
between the two drug classes have a differential impact on the 
affected angiotensin receptor subtypes, a different involve-
ment of peptide hormones other than Ang II, and possible 
differences in the efﬁcacy of RAS suppression. ACE-I reduce 
the stimulation of AT1 and AT2 receptors, but inhibition may 
be overcome by activation of renin, by induction of ACE, 
and by alternative Ang II forming enzymes such as chymase. 
Inhibition of ACE blocks the degradation of various peptides, 
especially the vasodilator bradykinin. ACE-I potentiate the 
effects of bradykinin by 3–50-fold (Bonner et al 1990). 
Bradykinin stimulates NO-release from endothelial cells via 
B2-receptors (Unger, 2002). These effects might contribute 
to the antihypertensive effects of ACE-I.
Effect of ACE-I and ARBs on Ang-(1–7) 
generation
Drug therapy with an ACE-I compared with ARB-therapy 
exerts different effects on the RAS-balance. Pharmaco-
logically blocking ACE results in lower circulating Ang II 
peptide levels which means that less substrate is available 
for ACE2 and for Ang-(1–7)-generation. The catabolism 
of Ang-(1–7) and Ang II- levels is decreased by ACE-I-
treatment, whereas the level of Ang I which is a substrate 
for Ang-(1–7)-forming enzymes to generate Ang-(1–7) 
is increased. Ang-(1–7) can then act via the mas-receptor Vascular Health and Risk Management 2007:3(1) 133
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(see also Figure 1). The observation that the Ang-(1–7) 
antagonist D-Ala7-Ang-(1–7) reverts the potentiation of 
bradykinin by enalapril or enalaprilat in mesenteric   
microvessels (Fernandes et al 2001), or attenuates the 
potential hypotensive response to BK in captopril-treated 
rats (Maia et al 2004) indicates that an Ang-(1–7)-related 
mechanism signiﬁcantly contributes to the hypotensive and 
beneﬁcial effects of ACE-I.
ARBs completely block all effects mediated via the 
AT1-receptor which results in increased Ang II levels. 
This increase in circulating Ang II levels causes a shunt-
ing of Ang II to the unopposed AT2-receptor. It has been 
demonstrated experimentally that AT2-receptor stimulation 
enhances bradykinin-generation, so that some vasodilator 
or diuretic actions of ARB may arise through this pathway 
(Carey et al 2001). However, bradykinin potentiation by 
ARBs is less to that of ACE-I which might have impact 
on the therapeutically desired actions. On the other hand, 
AT1-receptor blockade prevents the AT1-mediated actions 
of Ang II and might hence be capable of potentiating its 
effects via AT2-receptors. However, work by Ferrario and 
colleagues found no evidence for a role of AT2-receptors 
in mediating the vasodilator response produce by long-term 
administration of lisinopril and losartan (Iyer et al 1998a, b, 
2000). In addition, increased levels of both Ang I and Ang 
II change the metabolic cascade through ACE2 towards 
Ang-(1–7)-generation as recent work demonstrated that 
administration of either losartan or olmesartan upregulated 
cardiac and renal ACE2 mRNA (Ishiyama et al 2004; Fer-
rario et al 2005a, b; Igase et al 2005; Jessup et al 2006). 
ACE-I and ARBs have important similarities because they 
block the same system but they also have several differ-
ences in their mechanisms of action, eg, regarding their 
effects on kinins, Ang-(1–7) and the AT2-receptor. The 
clinical relevance of these different therapeutic principles 
of RAS-blockade requires further study. Although beyond 
the scope of the present article there is also increasing in-
terest and evidence to support the combined use of ACE-I 
and ARB in various clinical settings such as heart failure 
(Burnier and Brunner 2000). The Candesartan in Heart 
Failure Assessment of Reduction in Morbidity and mor-
tality (CHARM) trial revealed that candesartan treatment 
signiﬁcantly reduced cardiovascular deaths and hospital 
admissions for heart failure (Pfeffer et al 2003). In addition, 
the COOPERATE-trial highlighted that combination treat-
ment of an ACE-I with an ARB safely retards progression 
of non-diabetic renal disease compared with monotherapy 
(Nakao et al 2003).
What this means in terms of the regulations and interplay 
of the components of the RAS is still widely unknown.
Is there scientiﬁc evidence for therapeutic superiority of 
either ARBs or ACE-I for any medical indication?
ACE-I and ARBs are successfully applied in the treat-
ment of hypertension, heart failure, diabetes and coronary 
heart disease (Dendorfer et al 2005). Although ACE-I and 
ARBs block the same system, they may have important 
differences because they act on different sites of the RAS. 
However, therapeutic superiority of ARBs over ACE-I 
has never been proven. International treatment guidelines 
for hypertension (Chobanian et al 2003) cite ACE-I and 
ARBs as equally effective in reducing blood pressure but 
explicitly recommend ARBs only in case of ACE-I induced 
cough (Stergiou and Skeva 2004). Although clinical trials 
with head to head comparison of ACE-I with ARBs are 
few, there is some evidence suggesting differences in their 
effect on insulin sensitivity (Moan et al 1996) and pulse 
pressure (Stergiou et al 2002). In addition, selective ARBs 
have consistently been shown to inhibit several physiologic 
mechanisms that are involved in the development of in-stent 
restenosis: neointimal formation, vascular smooth cell 
migration, oxidative stress, anti-inﬂammatory effects and 
suppression of smooth muscle cell differentiation. There is 
increasing evidence from clinical studies that ARBs reduce 
restenosis rates after coronary (Peters et al 2001; Yoshida et al 
2005) or superﬁcial femoral artery stenting (Schindler et al 
2005) whereas ACE-I do not have these beneﬁcial effects 
(Faxon 1995; Cashin-Hemphill et al 1999; MacMahon et al 
2000). Considering the pharmacological differences between 
ACE-I and ARBs it has to be pointed out that treatment 
with an ARB results in signiﬁcantly increased Ang-(1–7)-
peptide levels (Schindler et al 2007) whereas treatment 
with an ACE-I does not. Together with the experimental 
results of Langeveld (Langeveld et al 2005) who described a 
signiﬁcant reduction in neointimal thickness after Ang-(1–7) 
infusions in an experimental model after stent implantation 
one might speculate that increased Ang-(1–7)-levels might 
causally contribute to the improved outcomes documented 
with ARBs after vascular interventions whereas increased 
bradykinin-levels after treatment with an ACE-I do not seem 
to have beneﬁcial vascular effects. This hypothesis should be 
conﬁrmed in large, randomized controlled clinical studies.
However, the signiﬁcance of most of the reported dif-
ferences between the two drug classes remains largely   
unknown and in clinical practice the only clearly established 
advantage of ARBs over ACE-I is the absence of cough as 
a side effect.Vascular Health and Risk Management 2007:3(1) 134
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Other cardiovascular drugs with 
therapeutic implications on the RAS
Renin-inhibitors
Experimental and clinical studies have indicated that 
blockade of the RAS is an important therapeutic strategy 
in reducing cardiovascular and renal disease. However, the 
therapeutic response achieved with currently available block-
ers of the RAS – angiotensin-converting-enzyme-inhibitors 
and angiotensin receptor blockers – although efﬁcacious, 
is limited. This may be partly because of the reactive rise 
in renin induced by these agents with the resultant increase 
in angiotensin peptides. Therefore, other more effective 
strategies to block the RAS have been sought. Just recently 
a new renin inhibitor (aliskiren) was FDA-approved for 
the treatment of hypertension in April 2007 (for review see 
(Azizi et al 2006)). Renin inhibitors prevent the formation of 
Ang I and Ang II and so may act differently from ARBs and 
ACE-I. Currently there is no published data from preclinical 
or clinical studies investigating the inﬂuence of pharmaco-
logical renin-inhibition on either urinary or serum peptide 
levels of Ang-(1–7).
Vasopeptidase-inhibitors
Drugs that possess the ability to inhibit simultaneously ACE 
and the neutral endopeptidase 24.11 (NEP) represent another 
development of compounds affecting the RAS. These dual 
inhibitors, also named vasopeptidase inhibitors, decrease 
Ang II generation by inhibiting ACE activity, and reduce the 
metabolic degradation of natriuretic peptides by inhibiting 
NEP. Natriuretic peptides represent a family of peptides that 
include the atrial natriuretic peptide (ANP), the BNP, and the 
C-type natriuretic peptide (CNP). Bradykinin and substance 
P are two other peptides metabolized by ACE and NEP, the 
accumulation of which may contribute to the vasodilatory 
effects of dual inhibitors.
Ferrario et al (Ferrario et al 2002a) found a strong cor-
relation between the antihypertensive response to omapa-
trilat and increases in urinary excretion rates of Ang I and 
Ang-(1–7) in spontaneously hypertensive rats and also in 
salt-sensitive hypertensive subjects (Ferrario et al 2002b) 
suggesting a contribution of Ang-(1–7) to the vasodilator 
response mediated by this agent. This important association 
between increases in both plasma and urinary Ang-(1–7) and 
the antihypertensive effect of omapatrilat suggests, even if 
it does not prove, that Ang-(1–7) as humoral regulator may 
play a contributing role in the mechanisms that account for 
the control of blood pressure.
However, omapatrilat as the prototype of drugs with this 
pharmacological principle of dual inhibition was clinically 
developed but never got ﬁnal approval by the health authori-
ties due to unforeseen side-effects.
Perspectives
Ang-(1–7) as potential cardiovascular 
drug target
Besides its direct vascular effects which are not completely 
clear in humans, Ang-(1–7) can act as an ACE-I and as an 
Ang II antagonist and facilitates the vascular and cardiac 
effects of bradykinin, making it an attractive target for the 
development of new cardiovascular drugs. The growing 
evidence that at least part of the beneﬁcial effects of ACE-I 
and ARBs are mediated by Ang-(1–7) further strengthens this 
view. The recently described model compound AVE-0991 
is the ﬁrst available Ang-(1–7) receptor agonist. A recently 
published study (Wiemer et al 2002) demonstrated that the 
new nonpeptide compound AVE 0991 is able to evoke effects 
on endothelial cells similar to that observed for heptapeptide 
Ang-(1–7). The amount of AVE 0991-stimulated NO produc-
tion was about ﬁve times higher than that stimulated by Ang-
(1–7) (Wiemer et al 2002). In addition it was experimentally 
shown that AVE is an Ang-(1–7) receptor mas-receptor ago-
nist (Pinheiro et al 2004). This promising drug characteristic 
makes the orally active Ang-(1–7)-agonist AVE-0991, as a 
potent mimic of the unique NO/O2-releasing proﬁle of Ang-
(1–7), an attractive target for further future development for 
patients, eg, for indications such as endothelial dysfunction 
and stable coronary heart disease. Besides their potential as 
vascular drugs Ang-(1–7) or other mas-receptor-agonists 
might also exert beneﬁcial effects on structural organ disease 
such as myocardial ﬁbrosis which is a key pathological pro-
cess in left ventricular hypertrophy. The optimal treatment 
of hypertensive patients should target a parallel decrease in 
cardiac mass and ﬁbrosis. Preliminary evidence suggests that 
not all antihypertensive agents affect ﬁbrosis to the same 
extent. However, agents directly blocking the RAS such 
as ACE-I and ARBs appear particularly effective (Cuspidi   
et al 2006) which underlines that mas-receptor-agonists might 
have a therapeutic potential and should be systematically 
investigated for this indication.
In addition, the presence of polymorphisms in the 
Ang-(1–7) forming enzyme genes and ACE2 need further 
exploration as we showed that men with the T allele showed 
higher Ang-(1–7) levels compared with those with the MM 
genotype (Reyes-Engel et al 2006). Furthermore, additional Vascular Health and Risk Management 2007:3(1) 135
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studies should be directed to determine whether the efﬁcacy 
of long-term effects of ACE-I or ARB on cardiac remodeling 
and preservation of renal function correlates with the effect 
of these drugs on plasma levels of Ang-(1–7).
Conclusion
Ang-(1–7) as the most pleiotropic angiotensin peptide 
can act at several levels on the RAS, counterbalancing the 
detrimental vascular effects consequent to Ang I and Ang 
II formation and is therefore an attractive candidate as a 
therapeutic drug target. The majority of clinical studies in-
vestigating cardiovascular effects of Ang-(1–7) are in favor 
of beneﬁcial RAS-modulating effects. Conﬂicting evidence 
about the RAS-modulating role of Ang-(1–7) reported from 
human studies might be related to extremely low case num-
bers investigated and due to different study protocols. The 
relevance of beneﬁcial effects of Ang-(1–7) for patients on 
therapy with ACE-I or ARBs should therefore be systemati-
cally studied in randomized controlled trials in humans.
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